Dr. Reddy's Laboratories Competitors

Alexion Pharmaceuticals (NASDAQ:ALXN) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider & Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Alexion Pharmaceuticals and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Alexion Pharmaceuticals and Dr. Reddy's Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Dr. Reddy's Laboratories. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Alexion Pharmaceuticals and Dr. Reddy's Laboratories, as reported by MarketBeat.com.

Alexion Pharmaceuticals presently has a consensus price target of $159.3158, indicating a potential downside of 7.27%. Dr. Reddy's Laboratories has a consensus price target of $70.00, indicating a potential downside of 3.05%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Alexion Pharmaceuticals.

Volatility and Risk

Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Dr. Reddy's Laboratories on 11 of the 14 factors compared between the two stocks.

Dr. Reddy's Laboratories (NYSE:RDY) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Profitability

This table compares Dr. Reddy's Laboratories and BeiGene's net margins, return on equity and return on assets.

Insider & Institutional Ownership

12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 60.7% of BeiGene shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 9.0% of BeiGene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Dr. Reddy's Laboratories and BeiGene's top-line revenue, earnings per share and valuation.

Dr. Reddy's Laboratories has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Dr. Reddy's Laboratories has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Dr. Reddy's Laboratories and BeiGene, as reported by MarketBeat.com.

Dr. Reddy's Laboratories presently has a consensus price target of $70.00, suggesting a potential downside of 3.05%. BeiGene has a consensus price target of $317.1250, suggesting a potential upside of 4.55%. Given BeiGene's higher possible upside, analysts clearly believe BeiGene is more favorable than Dr. Reddy's Laboratories.

Summary

Dr. Reddy's Laboratories beats BeiGene on 8 of the 14 factors compared between the two stocks.

Dr. Reddy's Laboratories (NYSE:RDY) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Dr. Reddy's Laboratories and Royalty Pharma, as reported by MarketBeat.com.

Dr. Reddy's Laboratories presently has a consensus price target of $70.00, suggesting a potential downside of 3.05%. Royalty Pharma has a consensus price target of $51.8750, suggesting a potential upside of 25.03%. Given Royalty Pharma's higher possible upside, analysts clearly believe Royalty Pharma is more favorable than Dr. Reddy's Laboratories.

Profitability

This table compares Dr. Reddy's Laboratories and Royalty Pharma's net margins, return on equity and return on assets.

Dividends

Dr. Reddy's Laboratories pays an annual dividend of $0.27 per share and has a dividend yield of 0.4%. Royalty Pharma pays an annual dividend of $0.68 per share and has a dividend yield of 1.6%. Dr. Reddy's Laboratories pays out 9.7% of its earnings in the form of a dividend. Royalty Pharma has raised its dividend for 1 consecutive years. Royalty Pharma is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Earnings & Valuation

This table compares Dr. Reddy's Laboratories and Royalty Pharma's top-line revenue, earnings per share and valuation.

Dr. Reddy's Laboratories has higher revenue and earnings than Royalty Pharma.

Institutional and Insider Ownership

12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 40.9% of Royalty Pharma shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 2.5% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Royalty Pharma beats Dr. Reddy's Laboratories on 7 of the 12 factors compared between the two stocks.

Genmab A/S (NASDAQ:GMAB) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Genmab A/S and Dr. Reddy's Laboratories, as reported by MarketBeat.com.

Genmab A/S presently has a consensus price target of $41.5714, suggesting a potential upside of 11.63%. Dr. Reddy's Laboratories has a consensus price target of $70.00, suggesting a potential downside of 3.05%. Given Genmab A/S's higher possible upside, equities research analysts plainly believe Genmab A/S is more favorable than Dr. Reddy's Laboratories.

Insider and Institutional Ownership

6.2% of Genmab A/S shares are owned by institutional investors. Comparatively, 12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Genmab A/S and Dr. Reddy's Laboratories' top-line revenue, earnings per share and valuation.

Genmab A/S has higher earnings, but lower revenue than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Genmab A/S and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

Volatility & Risk

Genmab A/S has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Summary

Genmab A/S beats Dr. Reddy's Laboratories on 8 of the 14 factors compared between the two stocks.

Dr. Reddy's Laboratories (NYSE:RDY) and CureVac (NASDAQ:CVAC) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Analyst Ratings

This is a summary of recent ratings for Dr. Reddy's Laboratories and CureVac, as reported by MarketBeat.com.

Dr. Reddy's Laboratories currently has a consensus target price of $70.00, suggesting a potential downside of 3.05%. CureVac has a consensus target price of $58.3333, suggesting a potential downside of 44.86%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than CureVac.

Earnings and Valuation

This table compares Dr. Reddy's Laboratories and CureVac's gross revenue, earnings per share (EPS) and valuation.

Dr. Reddy's Laboratories has higher revenue and earnings than CureVac.

Insider and Institutional Ownership

12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 4.3% of CureVac shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Dr. Reddy's Laboratories and CureVac's net margins, return on equity and return on assets.

Summary

Dr. Reddy's Laboratories beats CureVac on 8 of the 8 factors compared between the two stocks.

Dr. Reddy's Laboratories (NYSE:RDY) and Horizon Therapeutics Public (NASDAQ:HZNP) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Dr. Reddy's Laboratories and Horizon Therapeutics Public, as provided by MarketBeat.com.

Dr. Reddy's Laboratories currently has a consensus target price of $70.00, suggesting a potential downside of 3.05%. Horizon Therapeutics Public has a consensus target price of $111.3636, suggesting a potential upside of 29.13%. Given Horizon Therapeutics Public's higher possible upside, analysts clearly believe Horizon Therapeutics Public is more favorable than Dr. Reddy's Laboratories.

Earnings & Valuation

This table compares Dr. Reddy's Laboratories and Horizon Therapeutics Public's gross revenue, earnings per share and valuation.

Horizon Therapeutics Public has lower revenue, but higher earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 88.6% of Horizon Therapeutics Public shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 4.3% of Horizon Therapeutics Public shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Dr. Reddy's Laboratories and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Risk & Volatility

Dr. Reddy's Laboratories has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats Dr. Reddy's Laboratories on 10 of the 13 factors compared between the two stocks.